Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.
Identifieur interne : 00CC74 ( Main/Exploration ); précédent : 00CC73; suivant : 00CC75Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.
Auteurs : J. Kazura [États-Unis] ; J. Greenberg ; R. Perry ; G. Weil ; K. Day ; M. AlpersSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 1993.
Descripteurs français
- KwdFr :
- Adulte, Animaux, Antigènes d'helminthe (sang), Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Microfilaria, Mâle, Méthode en double aveugle, Noeuds lymphatiques (), Papouasie - Nouvelle-Guinée, Wuchereria bancrofti, Études de suivi.
- MESH :
- administration et posologie : Diéthylcarbamazine, Ivermectine.
- effets indésirables : Diéthylcarbamazine, Ivermectine.
- sang : Antigènes d'helminthe, Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine, Ivermectine.
- Adulte, Animaux, Humains, Microfilaria, Mâle, Méthode en double aveugle, Noeuds lymphatiques, Papouasie - Nouvelle-Guinée, Wuchereria bancrofti, Études de suivi.
English descriptors
- KwdEn :
- Adult, Animals, Antigens, Helminth (blood), Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Double-Blind Method, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Follow-Up Studies, Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (therapeutic use), Lymph Nodes (drug effects), Male, Microfilariae, Papua New Guinea, Wuchereria bancrofti.
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Ivermectin.
- chemical , adverse effects : Diethylcarbamazine, Ivermectin.
- chemical , blood : Antigens, Helminth.
- chemical , therapeutic use : Diethylcarbamazine, Ivermectin.
- blood : Elephantiasis, Filarial.
- drug effects : Lymph Nodes.
- drug therapy : Elephantiasis, Filarial.
- Adult, Animals, Double-Blind Method, Follow-Up Studies, Humans, Male, Microfilariae, Papua New Guinea, Wuchereria bancrofti.
Abstract
This double-blind study compared the clinical safety and parasitologic efficacy of single-dose regimens of diethylcarbamazine (DEC) and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. Five groups of 10 men each with mean levels of parasitemia ranging from 2,985 to 5,185 microfilariae (mf)/ml were given DEC (6 mg/kg of body weight one time or 1 mg/kg, then 6 mg/kg four days later) or ivermectin (220 micrograms/kg; 20 micrograms/kg, then 200 micrograms/kg four days later or 20 micrograms/kg, then 400 micrograms/kg four days later). No significant side effects (e.g., acute adenolymphangitis, fever lasting more than eight hours, hypotension) were observed in any of the five treatment groups. The magnitude of reduction in microfilaremia was greater (P < 0.01) for the three ivermectin groups versus the two DEC groups in the first 30 days after drug administration (mf levels < 1% of pretreatment values versus 22.6-41.5%, respectively). At 90 and 180 days, mf levels continued to decrease in the DEC groups whereas they increased in the ivermectin groups given a total dose of 220 micrograms/kg. Eighteen months after drug administration, individuals given DEC or 420 micrograms/kg of ivermectin had the greatest degree of reduction in microfilaremia (86-90% compared with the pretreatment values). Decreases in parasite antigenemia measured by enzyme-linked immunosorbent assay for a secreted 200-kD adult worm antigen were greatest for the single-dose DEC group (39.7% decrease relative to the pretreatment level versus 7.8-15.7% for the ivermectin groups). These results indicate that single-dose DEC and ivermectin are well-tolerated by Wuchereria bancrofti-infected individuals with high levels of microfilaremia.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 8279647
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005639
- to stream PubMed, to step Curation: 005639
- to stream PubMed, to step Checkpoint: 005639
- to stream Ncbi, to step Merge: 00B494
- to stream Ncbi, to step Curation: 00B494
- to stream Ncbi, to step Checkpoint: 00B494
- to stream Main, to step Merge: 00D704
- to stream Main, to step Curation: 00CC74
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.</title><author><name sortKey="Kazura, J" sort="Kazura, J" uniqKey="Kazura J" first="J" last="Kazura">J. Kazura</name><affiliation wicri:level="2"><nlm:affiliation>Division of Geographic Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Division of Geographic Medicine, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J" last="Greenberg">J. Greenberg</name></author><author><name sortKey="Perry, R" sort="Perry, R" uniqKey="Perry R" first="R" last="Perry">R. Perry</name></author><author><name sortKey="Weil, G" sort="Weil, G" uniqKey="Weil G" first="G" last="Weil">G. Weil</name></author><author><name sortKey="Day, K" sort="Day, K" uniqKey="Day K" first="K" last="Day">K. Day</name></author><author><name sortKey="Alpers, M" sort="Alpers, M" uniqKey="Alpers M" first="M" last="Alpers">M. Alpers</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8279647</idno><idno type="pmid">8279647</idno><idno type="wicri:Area/PubMed/Corpus">005639</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005639</idno><idno type="wicri:Area/PubMed/Curation">005639</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005639</idno><idno type="wicri:Area/PubMed/Checkpoint">005639</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005639</idno><idno type="wicri:Area/Ncbi/Merge">00B494</idno><idno type="wicri:Area/Ncbi/Curation">00B494</idno><idno type="wicri:Area/Ncbi/Checkpoint">00B494</idno><idno type="wicri:doubleKey">0002-9637:1993:Kazura J:comparison:of:single</idno><idno type="wicri:Area/Main/Merge">00D704</idno><idno type="wicri:Area/Main/Curation">00CC74</idno><idno type="wicri:Area/Main/Exploration">00CC74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.</title><author><name sortKey="Kazura, J" sort="Kazura, J" uniqKey="Kazura J" first="J" last="Kazura">J. Kazura</name><affiliation wicri:level="2"><nlm:affiliation>Division of Geographic Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Division of Geographic Medicine, Case Western Reserve University School of Medicine, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J" last="Greenberg">J. Greenberg</name></author><author><name sortKey="Perry, R" sort="Perry, R" uniqKey="Perry R" first="R" last="Perry">R. Perry</name></author><author><name sortKey="Weil, G" sort="Weil, G" uniqKey="Weil G" first="G" last="Weil">G. Weil</name></author><author><name sortKey="Day, K" sort="Day, K" uniqKey="Day K" first="K" last="Day">K. Day</name></author><author><name sortKey="Alpers, M" sort="Alpers, M" uniqKey="Alpers M" first="M" last="Alpers">M. Alpers</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Antigens, Helminth (blood)</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Double-Blind Method</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Follow-Up Studies</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Lymph Nodes (drug effects)</term><term>Male</term><term>Microfilariae</term><term>Papua New Guinea</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Antigènes d'helminthe (sang)</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Microfilaria</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Noeuds lymphatiques ()</term><term>Papouasie - Nouvelle-Guinée</term><term>Wuchereria bancrofti</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes d'helminthe</term><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Microfilariae</term><term>Papua New Guinea</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Humains</term><term>Microfilaria</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Noeuds lymphatiques</term><term>Papouasie - Nouvelle-Guinée</term><term>Wuchereria bancrofti</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This double-blind study compared the clinical safety and parasitologic efficacy of single-dose regimens of diethylcarbamazine (DEC) and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. Five groups of 10 men each with mean levels of parasitemia ranging from 2,985 to 5,185 microfilariae (mf)/ml were given DEC (6 mg/kg of body weight one time or 1 mg/kg, then 6 mg/kg four days later) or ivermectin (220 micrograms/kg; 20 micrograms/kg, then 200 micrograms/kg four days later or 20 micrograms/kg, then 400 micrograms/kg four days later). No significant side effects (e.g., acute adenolymphangitis, fever lasting more than eight hours, hypotension) were observed in any of the five treatment groups. The magnitude of reduction in microfilaremia was greater (P < 0.01) for the three ivermectin groups versus the two DEC groups in the first 30 days after drug administration (mf levels < 1% of pretreatment values versus 22.6-41.5%, respectively). At 90 and 180 days, mf levels continued to decrease in the DEC groups whereas they increased in the ivermectin groups given a total dose of 220 micrograms/kg. Eighteen months after drug administration, individuals given DEC or 420 micrograms/kg of ivermectin had the greatest degree of reduction in microfilaremia (86-90% compared with the pretreatment values). Decreases in parasite antigenemia measured by enzyme-linked immunosorbent assay for a secreted 200-kD adult worm antigen were greatest for the single-dose DEC group (39.7% decrease relative to the pretreatment level versus 7.8-15.7% for the ivermectin groups). These results indicate that single-dose DEC and ivermectin are well-tolerated by Wuchereria bancrofti-infected individuals with high levels of microfilaremia.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><noCountry><name sortKey="Alpers, M" sort="Alpers, M" uniqKey="Alpers M" first="M" last="Alpers">M. Alpers</name><name sortKey="Day, K" sort="Day, K" uniqKey="Day K" first="K" last="Day">K. Day</name><name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J" last="Greenberg">J. Greenberg</name><name sortKey="Perry, R" sort="Perry, R" uniqKey="Perry R" first="R" last="Perry">R. Perry</name><name sortKey="Weil, G" sort="Weil, G" uniqKey="Weil G" first="G" last="Weil">G. Weil</name></noCountry><country name="États-Unis"><region name="Ohio"><name sortKey="Kazura, J" sort="Kazura, J" uniqKey="Kazura J" first="J" last="Kazura">J. Kazura</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00CC74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00CC74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8279647
|texte= Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8279647" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |